Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Kura Oncology Q1 2026 Earnings Call - KOMZIFTI Launch Exceeds Expectations with 40% New Patient Share
Kura Oncology’s first full quarter as a commercial entity is off to a strong start. KOMZIFTI (ziftomenib) generated $5.8 million in net product revenue, driven by 85 new patient starts across 60 activ...
- KOMZIFTI generated $5.8 million in net product revenue in Q1 2026, surpassing management's initial expectations for the first full quarter of launch.
- The company secured 85 new patient starts across approximately 60 activated accounts, capturing roughly 40% of the new patient market share in the NPM1-mutant AML space despite being second-to-market.
- Physicians are actively switching patients from competing menin inhibitors to KOMZIFTI, signaling early product differentiation based on efficacy, safety, and dosing convenience.
- +7 more takeaways
MaxCyte Q1 2026 Earnings Call - Core Revenue Misses, but Restructuring and New Products Signal Turnaround
MaxCyte reported $9.7 million in Q1 2026 revenue, missing expectations as core revenue fell 25% year-over-year to $6.2 million due to inventory management at its largest customer and discontinued SPL ...
- Total revenue of $9.7 million missed expectations, driven by a 25% YoY decline in core revenue to $6.2 million due to inventory management at its largest customer and discontinued SPL programs.
- SPL program-related revenue rose 62% YoY to $3.4 million, including a $3 million regulatory milestone from a clinical customer dosing in a registrational study.
- Operating expenses fell $7 million YoY to $14.3 million, reflecting the full impact of 2025 restructuring and cost efficiency actions, with no meaningful OpEx growth expected going forward.
- +7 more takeaways
Nyxoah Q1 2026 Earnings Call - U.S. Revenue Acceleration and Reimbursement Clarity Drive Q2 Outlook
Nyxoah reported a strong start to 2026, with Q1 worldwide net revenue rising 13% sequentially to EUR 6.4 million, driven by a 25% surge in U.S. sales. The company achieved its first full quarter of U....
- Q1 2026 worldwide net revenue reached EUR 6.4 million, up 13% sequentially, with U.S. net revenue surging 25% to EUR 4.3 million.
- U.S. commercial execution is accelerating, with 40 active sales reps now covering 200 of the 400 targeted high-volume accounts.
- Surgeon adoption is deepening, with 207 total surgeons trained and 91 active accounts (surgeons trained and VAC committee approved) out of 125 targeted sites.
- +7 more takeaways
Verrica Pharmaceuticals First Quarter 2026 Earnings Call - YCANTH Sales Accelerate, Pipeline Advances
Verrica Pharmaceuticals reported accelerating demand for its molluscum treatment YCANTH in the first quarter of 2026, with U.S. revenue rising 25.4% year-over-year to $4.3 million and dispensed applic...
- U.S. YCANTH revenue rose 25.4% year-over-year to $4.3 million in Q1 2026, driven by a 51.3% increase in dispensed applicator units to 15,302.
- YCANTH achieved a new record for monthly dispensed applicator units in March 2026, with demand continuing to accelerate into April.
- Torii Pharmaceutical launched YCANTH in Japan for molluscum treatment in February 2026, following regulatory approval, marking a key international milestone.
- +7 more takeaways
Relmada Therapeutics Q1 2026 Earnings Call - Phase III RESCUE Program on Track with $160 Million War Chest and Compelling 12-Month Bladder Cancer Data
Relmada Therapeutics entered the second half of 2026 with a fortified balance sheet and clear regulatory pathways. The company secured $160 million in private financing, pushing its cash position to $...
- Relmada closed Q1 2026 with a cash balance of $234 million, following a $160 million private placement completed in March 2026. This fortifies the balance sheet and provides sufficient runway to fund operations and complete the Phase III RESCUE program through 2029.
- The company remains on track to initiate the Phase III RESCUE registrational program for NDV-01 in mid-2026, following successful FDA alignment on the trial design and endpoints.
- NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel, demonstrated a 76% complete response (CR) rate at 12 months in the overall Phase II population of high-risk non-muscle invasive bladder cancer (NMIBC).
- +9 more takeaways
Stereotaxis Q1 2026 Earnings Call - New Disposable Ecosystem Begins to Replace Legacy J&J Supply
Stereotaxis is navigating a painful but structurally transformative transition. The company is actively winding down its two-decade-old dependency on Johnson & Johnson catheters while rolling out an e...
- Revenue of $6.3 million in Q1 2026, down from $7.5 million year-ago, reflecting a transitional period as legacy J&J catheter supply winds down before the new disposable ecosystem scales.
- Management is actively replacing a 20-year dependency on Johnson & Johnson catheters with a new proprietary disposable business, expecting annual revenue to surpass $40 million with double-digit growth.
- Initial MAGiC catheter procedures are generating $5,000 to $8,000 in recurring revenue per case, a massive step-up from legacy hardware sales, with European hospitals already ordering $100,000 in disposables for a single month.
- +9 more takeaways
TriSalus Life Sciences Q1 2026 Earnings Call - Landmark Real-World Evidence Validates PEDD, Commercial Expansion Drives Revenue Transition
TriSalus Life Sciences reported a deliberate but costly transition in its first quarter, as a massive commercial expansion temporarily disrupted sales while laying the groundwork for future growth. Re...
- Revenue for Q1 2026 was $8.9 million, slightly down from $9.2 million in the prior year period, primarily due to transition costs associated with a major commercial expansion.
- Gross margin improved to 86% from 84% in the prior year, driven by lower average unit costs on TriNav and continuous manufacturing improvements.
- The company is executing a deliberate commercial realignment, doubling its sales force and expanding its territory footprint to capture growth across a $2.5 billion addressable market.
- +11 more takeaways
GrowGeneration Q1 2026 Earnings Call - Commercial B2B Momentum and Proprietary Brand Expansion Drive Revenue Growth
GrowGeneration delivered its second consecutive quarter of year-over-year revenue growth in Q1 2026, with net sales rising 7.5% to $38.4 million. The company’s strategic pivot toward a commercially dr...
- GrowGeneration reported Q1 2026 net sales of $38.4 million, up 7.5% year-over-year, marking its second consecutive quarter of revenue growth.
- Proprietary brand sales now represent 37% of cultivation and gardening revenue, up from 32% in the prior year, reflecting a strategic shift toward higher-margin, recurring consumable products.
- The storage solutions segment drove significant growth, with net sales increasing 35.5% year-over-year to $6.5 million, benefiting from increased capital investment across broader end markets.
- +7 more takeaways
a.k.a. Brands Q1 2026 Earnings Call - Gross Margin Expansion Signals Structural Turnaround
a.k.a. Brands delivered a resilient first quarter, with net sales rising 3% to $132.5 million and Adjusted EBITDA jumping to $5.1 million, well above prior expectations. The headline story is the 180 ...
- Net sales grew 3% year-over-year to $132.5 million, slightly ahead of company guidance, driven by 3.2% U.S. sales growth and 3.8% Australian sales growth.
- Adjusted EBITDA more than doubled to $5.1 million from $2.7 million, with the margin expanding 180 basis points to 3.9%.
- Underlying gross margin expanded 180 basis points to 59%, fueled by inventory discipline, stronger full-price sell-through, and the rollout of the test-and-repeat model, primarily in the streetwear division.
- +7 more takeaways
Fractyl Health Q1 2026 Earnings Call - Pivotal Data Countdown and Capital Discipline
Fractyl Health reported a shift to net income in Q1 2026, driven by a $30.1 million non-cash accounting adjustment, while maintaining a disciplined cash runway into early 2027. The company is advancin...
- Revita Pivotal Trial on Track: The REMAIN-1 pivotal study completed randomizations in February with over 300 participants across 30+ sites. Top-line 6-month data is expected in early Q4 2026, with management targeting a strong result defined as roughly a 50% reduction in weight regain compared to the expected 15% rebound in GLP-1 discontinuers.
- Capital Discipline and Runway: Fractyl Health holds approximately $63.2 million in cash and cash equivalents as of March 31, 2026. Management explicitly closed its ATM facility and committed to no capital raises before pivotal data, extending runway into early 2027 to fund operations and the Rejuva program.
- Rejuva Gene Therapy Advances: Fractyl received authorization from the Netherlands to initiate the phase I/II first-in-human study for RJVA-001, an AAV-based gene therapy for type 2 diabetes. First patient dosing is expected in H2 2026, funded within existing cash runway.
- +7 more takeaways